Castle Creek Arbitrage’s Phoenix Biotech Acquisition Corp. Unit PBAXU Stock Holding History

Castle Creek Arbitrage’s Portfolio PBAXU Stock Details PBAXU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-400,000	Closed	-$4.04M	–	578
2022 Q3	$4.04M	Hold	400,000	–	–	0.22%	130
2022 Q2	$4.03M	Hold	400,000	–	–	0.22%	122
2022 Q1	$4.02M	Hold	400,000	–	–	0.2%	140
2021 Q4	$4.04M	Buy	+400,000	New	+$4.05M	0.2%	136

Other funds holding PBAXU

YCM

Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return

FTUS

Flow Traders U.S. New York $2.43B AUM 44.44% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Castle Creek Arbitrage's PBAXU Position: Q4 2022 in Review

Castle Creek Arbitrage sold out of Phoenix Biotech Acquisition Corp. Unit (PBAXU) in Q4 2022, closing a stake of 400,000 shares — an estimated $4.04M sold.

Castle Creek Arbitrage first reported a position in PBAXU in Q4 2021 and held it in 4 quarters. The position peaked at $4.04M in Q3 2022. 3 funds tracked by Wall St. Rank hold PBAXU as of Q4 2022.

Castle Creek Arbitrage reported no remaining Phoenix Biotech Acquisition Corp. Unit position as of Q4 2022 after selling out during the quarter.
Castle Creek Arbitrage sold 400,000 Phoenix Biotech Acquisition Corp. Unit shares in Q4 2022, an estimated $4.04M.
Castle Creek Arbitrage first reported a position in Phoenix Biotech Acquisition Corp. Unit in Q4 2021 and held it in 4 quarters.
Castle Creek Arbitrage's Phoenix Biotech Acquisition Corp. Unit position peaked at $4.04M in Q3 2022.
3 funds tracked by Wall St. Rank held Phoenix Biotech Acquisition Corp. Unit as of Q4 2022.

Based on Castle Creek Arbitrage's 13F filing for Q4 2022, filed 14 Feb 2023.